Abstract
In Europe, the USA and Australia the prevalence of smoking during pregnancy ranges between 10 and 27 %. Drinking alcohol is reported by 8.5–19.5 % of pregnant women, with a potentially significant number of unreported cases. Additionally, there are as many as 60,000–100,000 pregnant women using illicit drugs per year, with a high percentage of poly-drug users. Substance-dependent women have a high incidence of co-morbid psychiatric disorders, with DSM-IV axis I affective and post-traumatic stress as well as axis II personality disorders being the most frequent co-morbidities. Due to serious consequences of licit and illicit substance use during pregnancy as well as undetected/untreated psychiatric co-morbidities, the primary focus must be on adequate diagnostic assessment. Treatment, tailored individually to the kind of substance dependence and under consideration of evidence-based treatment options available as early as possible during pregnancy, leads to better pregnancy outcomes and fewer birth complications. Neonates born to mothers who are chronic illicit drug users or provided maternal medication-assisted treatment frequently develop a Neonatal Abstinence Syndrome (NAS). Pharmacological NAS treatment should be provided based on principles of accurate assessment and diagnosis, with non-pharmacological measures such as rooming-in being vital supportive interventions. The economic burden of substance dependence during pregnancy and related follow-up costs are significant. To lower societal costs and increase the quality of life of both mothers and children, international treatment standards, building on previous recommendations, must be established and implemented.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abrahams RR, Kelly SA, Payne S, Thiessen PN, Mackintosh J, Janssen PA. Rooming-in compared with standard care for newborns of mothers using methadone or heroin. Can Fam Physician. 2007;53(10):1722–30.
Administration USFaD. FDA Drug Safety Communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies; 2011.
Alcohol consumption, alcohol dependence and attributable burden of disease in Europe 2012. Available from: http://amphoraproject.net/w2box/data/AMPHORAReports/CAMH_Alcohol_Report_Europe_2012.pdf
Anagnostis EA, Sadaka RE, Sailor LA, Moody DE, Dysart KC, Kraft WK. Formulation of buprenorphine for sublingual use in neonates. J Pediatr Pharmacol Ther. 2011;16(4):281–4.
Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191(2):398–407.
Arlettaz R, Kashiwagi M, Das-Kundu S, Fauchere JC, Lang A, et al. Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources. Acta Obstet Gynecol Scand. 2005;84(2):145–50.
Askin DF, Diehl-Jones B. Cocaine: effects of in utero exposure on the fetus and neonate. J Perinat Neonatal Nurs. 2001;14(4):83–102.
Australian Institute of Health and Welfare. National Drug Strategy Household Survey: First Results Canberra (AUST): AIHW; 2004–2005.
Back SE, Sonne SC, Killeen T, Dansky BS, Brady KT. Comparative profiles of women with PTSD and comorbid cocaine or alcohol dependence. Am J Drug Alcohol Abuse. 2003;29(1):169–89.
Bada HS, Das A, Bauer CR, Shankaran S, Lester B, Wright LL, et al. Gestational cocaine exposure and intrauterine growth: maternal lifestyle study. Obstet Gynecol. 2002;100(5 Pt 1):916–24.
Baewert A, Jagsch R, Winklbaur B, Kaiser G, Thau K, Unger A, et al. Influence of site differences between urban and rural American and Central European opioid-dependent pregnant women and neonatal outcome characteristics. Eur Addict Res. 2012;18(3):130–9.
Behrendt H, Green M. Nature of the sweating deficit of prematurely born neonates. Observations on babies with the heroin withdrawal syndrome. N Engl J Med. 1972;286(26):1376–9.
Benningfield MM, Arria AM, Kaltenbach K, Heil SH, Stine SM, Coyle MG, et al. Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women. Am J Addict. 2010;19(5):416–21.
Berghella V, Lim PJ, Hill MK, Cherpes J, Chennat J, Kaltenbach K. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol. 2003;189(2):312–7.
Brose LS, McEwen A, West R. Association between nicotine replacement therapy use in pregnancy and smoking cessation. Drug Alcohol Depend. 2013;132(3):660–4.
Burns L, Mattick RP, Cooke M. Use of record linkage to examine alcohol use in pregnancy. Alcohol Clin Exp Res. 2006;30(4):642–8.
Chang G, McNamara TK, Orav EJ, Koby D, Lavigne A, Ludman B, et al. Brief intervention for prenatal alcohol use: a randomized trial. Obstet Gynecol. 2005;105(5 Pt 1):991–8.
Clare CA, Yeh J. Postpartum depression in special populations: a review. Obstet Gynecol Surv. 2012;67(5):313–23.
Cleary BJ, Donnelly J, Strawbridge J, Gallagher PJ, Fahey T, Clarke M, et al. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction. 2010;105(12):2071–84.
Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006;67(2):247–57.
Coyle MG, Ferguson A, Lagasse L, Oh W, Lester B. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr. 2002;140(5):561–4.
Daley M, Argeriou M, McCarty D, Callahan Jr JJ, Shepard DS, et al. The impact of substance abuse treatment modality on birth weight and health care expenditures. J Psychoactive Drugs. 2001;33(1):57–66.
D’Apoliti K, Finnegan LP. Assessing signs & symptoms of neonatal abstinence using the Finnegan scoring tool, an Inter-Observer Reliability Program. 2010. Available from: http://www.neoadvances.com
Davis EP, Glynn LM, Schetter CD, Hobel C, Chicz-Demet A, et al. Prenatal exposure to maternal depression and cortisol influences infant temperament. J Am Acad Child Adolesc Psychiatry. 2007;46(6):737–46.
Daw JR, Hanley GE, Greyson DL, Morgan SG. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf. 2011;20(9):895–902.
Degenhardt L, Day C, Gilmour S, Hall W. The “lessons” of the Australian “heroin shortage”. Subst Abuse Treat Prev Policy. 2006;1:11.
De Genna NM, Feske U, Angiolieri T, Gold MA. Race and sexually transmitted diseases in women with and without borderline personality disorder. J Womens Health. 2011;20(3):333–40.
De Genna NM, Feske U, Larkby C, Angiolieri T, Gold MA. Pregnancies, abortions, and births among women with and without borderline personality disorder. Womens Health Issues. 2012;22(4):e371–7.
Department of Health and Human Services. Results from the 2005 National Survey on Drug Use and Health: National Findings. Rockville, MD: DHHS; 2006.
De Santis M, De Luca C, Mappa I, Quattrocchi T, Angelo L, et al. Smoke, alcohol consumption and illicit drug use in an Italian population of pregnant women. Eur J Obstet Gynecol Reprod Biol. 2011;159(1):106–10.
Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr. 1991;118(6):933–7.
Doberczak TM, Kandall SR, Friedmann P. Relationship between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet Gynecol. 1993;81(6):936–40.
Dolan M, Vollm B. Antisocial personality disorder and psychopathy in women: a literature review on the reliability and validity of assessment instruments. Int J Law Psychiatry. 2009;32(1):2–9.
Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. Br J Obstet Gynaecol. 2009;116(5):665–71.
Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165(2):179–87.
Ebner N, Rohrmeister K, Winklbaur B, Baewert A, Jagsch R, et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend. 2007;87(2–3):131–8.
Egen-Lappe V, Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol. 2004;60(9):659–66.
El-Bassel N, Gilbert L, Wu E, Go H, Hill J. Relationship between drug abuse and intimate partner violence: a longitudinal study among women receiving methadone. Am J Public Health. 2005;95(3):465–70.
European Medicine Agency. 2007. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003515.pdf
European Monitoring Centre for Drugs and Drug Addiction. 2012. Available from: http://www.ofdt.fr/BDD/publications/docs/OEDT121031siGEF.pdf
Finnegan LP, Kron RE, Connaugthon JF, Emich JP. A scoring system for evaluation and treatment of the neonatal abstinence syndrome: A clinical and research tool. In: Morselli PL, Garattini S, Sereni F, editors. Basic and therapeutic aspects of perinatal pharmacology. New York, NY: Raven; 1975. p. 139–53.
Finnegan L. Clinical effects of pharmacologic agents on pregnancy, the fetus, and the neonate. Ann N Y Acad Sci. 1976;281:74–89.
Finnegan LP. Pulmonary problems encountered by the infant of the drug-dependent mother. Clin Chest Med. 1980;1(3):311–25.
Finnegan LP. Neonatal abstinence syndrome: assessment and pharmacotherapy. In: Rubaltelli B, Granati B, editors. Neonatal therapy: an update. New York, NY: Excerpta Medica; 1986. p. 122–46.
Finnegan LP. Treatment issues for opioid-dependent women during the perinatal period. J Psychoactive Drugs. 1991;23(2):191–201.
Finnegan LP, Kandall SR. Perinatal substance Use. In: Galanter M, Kleber H, editors. Textbook of substance abuse treatment. Arlington, VA: American Psychiatric Publishing; 2004.
Finnegan LP, Kandall SR. Maternal and neonatal effects of alcohol and drugs. In: Lowinson JH, Ruiz P, Langrod J, editors. Substance abuse: a comprehensive textbook. Baltimore, MD: Lippincot Williams and Wilson; 2005.
Finnegan LP, Kandall SR. Perintal substance use, drug dependence, motherhood, and the newborn. In: Galanter M, Kleber H, editors. Textbook of substance abuse treatment. Arlington, VA: American Psychiatric Publishing; 2008.
Fischer G. Review of the literature on pregnancy and psychosocially assisted pharmacotherapy of opioid dependence (including withdrawal management, agonist and antagonist maintenance therapy and adjuvant pharmacotherapy). 1–39 Geneva, Switzerland; 2007.
Fitzsimons HE, Tuten M, Vaidya V, Jones HE. Mood disorders affect drug treatment success of drug-dependent pregnant women. J Subst Abuse Treat. 2007;32(1):19–25.
Franck L, Vilardi J. Assessment and management of opioid withdrawal in ill neonates. Neonatal Netw. 1995;14(2):39–48.
Glass L, Rajegowda BK, Kahn EJ, Floyd MV. Effect of heroin withdrawal on respiratory rate and acid-base status in the newborn. N Engl J Med. 1972;286(14):746–8.
Goel N, Beasley D, Rajkumar V, Banerjee S. Perinatal outcome of illicit substance use in pregnancy–comparative and contemporary socio-clinical profile in the UK. Eur J Pediatr. 2011;170(2):199–205.
Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371(9606):75–84.
Green M, Suffet F. The Neonatal Narcotic Withdrawal Index: a device for the improvement of care in the abstinence syndrome. Am J Drug Alcohol Abuse. 1981;8(2):203–13.
Greenfield SF, Back SE, Lawson K, Brady KT. Substance abuse in women. Psychiatr Clin North Am. 2010;33(2):339–55.
Gyarmathy VA, Giraudon I, Hedrich D, Montanari L, Guarita B, et al. Drug use and pregnancy - challenges for public health. Euro Surveill. 2009;14(9):33–6.
Gynecologists ACoOa. Committee on Health Care for underserved Women and the American Society of Addicition Medicine “Opioid Abuse, Dependence, and Addicition in Pregnancy”. Obstetrics & Gynecology, Commitee Opinion. 2012; p. 524
Haasen C, Prinzleve M, Zurhold H, Rehm J, Guttinger F, et al. Cocaine use in Europe - a multi-centre study. Methodology and prevalence estimates. Eur Addict Res. 2004;10(4):139–46.
Haddad PM, Pal BR, Clarke P, Wieck A, Sridhiran S. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome? J Psychopharmacol. 2005;19(5):554–7.
Havens JR, Cornelius LJ, Ricketts EP, Latkin CA, Bishai D, et al. The effect of a case management intervention on drug treatment entry among treatment-seeking injection drug users with and without comorbid antisocial personality disorder. J Urban Health. 2007;84(2):267–71.
Havens JR, Simmons LA, Shannon LM, Hansen WF. Factors associated with substance use during pregnancy: results from a national sample. Drug Alcohol Depend. 2009;99(1–3):89–95.
Headley J, Northstone K, Simmons H, Golding J. Medication use during pregnancy: data from the Avon Longitudinal Study of Parents and Children. Eur J Clin Pharmacol. 2004;60(5):355–61.
Heberlein A, Leggio L, Stichtenoth D, Hillemacher T. The treatment of alcohol and opioid dependence in pregnant women. Curr Opin Psychiatry. 2012;25(6):559–64.
Heil SH, Jones HE, Arria A, Kaltenbach K, Coyle M, et al. Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat. 2011;40(2):199–202.
Henry A, Crowther C. Patterns of medication use during and prior to pregnancy: the MAP study. Aust N Z J Obstet Gynaecol. 2000;40(2):165–72.
Herzlinger RA, Kandall SR, Vaughan Jr HG. Neonatal seizures associated with narcotic withdrawal. J Pediatr. 1977;91(4):638–41.
Higgins ST, Washio Y, Heil SH, Solomon LJ, Gaalema DE, et al. Financial incentives for smoking cessation among pregnant and newly postpartum women. Prev Med. 2012;55(Suppl):S33–40.
Hodgson ZG, Abrahams RR. A rooming-in program to mitigate the need to treat for opiate withdrawal in the newborn. J Obstet Gynaecol Can. 2012;34(5):475–81.
Holbrook A, Kaltenbach K. Co-occurring psychiatric symptoms in opioid-dependent women: the prevalence of antenatal and postnatal depression. Am J Drug Alcohol Abuse. 2012;38(6):575–9.
Hudak ML, Tan RC, Committee on Drugs, Committee on Fetus and Newborn, American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540–60.
Johnson RE, Jones HE, Jasinski DR, Svikis DS, Haug NA, et al. Buprenorphine treatment of pregnant opioid–dependent women: maternal and neonatal outcomes. Drug Alcohol Depend. 2001;63(1):97–103.
Jones HE, Burns L, Gourarier L, Peles E, Springer-Kremser M, et al. A multi-national pre-consensus survey: the principles of treatment of substance Use disorders during pregnancy. Drug Alcohol Depend. 2010a;70(3):327–30.
Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010b;363(24):2320–31.
Jones TB, Bailey BA, Sokol RJ. Alcohol use in pregnancy: insights in screening and intervention for the clinician. Clin Obstet Gynecol. 2013;56(1):114–23.
Kaltenbach K, Holbrook AM, Coyle MG, Heil SH, Salisbury AL, et al. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction. 2012;107 Suppl 1:45–52.
Kandel DB, Huang FY, Davies M. Comorbidity between patterns of substance use dependence and psychiatric syndromes. Drug Alcohol Depend. 2001;64(2):233–41.
Kennare R, Heard A, Chan A. Substance use during pregnancy: risk factors and obstetric and perinatal outcomes in South Australia. Aust N Z J Obstet Gynaecol. 2005;45(3):220–5.
Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8–19.
Kessler RC. The epidemiology of dual diagnosis. Biol Psychiatry. 2004;56(10):730–7.
Klug MG, Burd L. Fetal alcohol syndrome prevention: annual and cumulative cost savings. Neurotoxicol Teratol. 2003;25(6):763–5.
Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, et al. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction. 2011;106(3):574–80.
Kraigher D, Schindler S, Ortner R, Fischer G. Pregnancy and substance dependency. Gesundheitswesen. 2001;63 Suppl 2:S101–5.
Law KL, Stroud LR, LaGasse LL, Niaura R, Liu J, et al. Smoking during pregnancy and newborn neurobehavior. Pediatrics. 2003;111(6 Pt 1):1318–23.
Lim S, Prasad MR, Samuels P, Gardner DK, Cordero L. High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. Am J Obstet Gynecol. 2009;200(1):70e1–70.e5.
Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clin Pediatr. 1975;14(6):592–4.
Lumley J, Chamberlain C, Dowswell T, Oliver S, Oakley L, Watson L. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2009 (3):CD001055.
Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med. 2009;163(10):949–54. Erratum in: Arch Pediatr Adolesc Med. 2009 Dec;163(12):1143.
Madden JD, Chappel JN, Zuspan F, Gumpel J, Mejia A, et al. Observation and treatment of neonatal narcotic withdrawal. Am J Obstet Gynecol. 1977;127(2):199–201.
Mangham LJ, Petrou S, Doyle LW, Draper ES, Marlow N. The cost of preterm birth throughout childhood in England and Wales. Pediatrics. 2009;123(2):e312–27.
Martin PR, Arria AM, Fischer G, Kaltenbach K, Heil SH, et al. Psychopharmacologic management of opioid-dependent women during pregnancy. Am J Addict. 2009;18(2):148–56.
Martin JA, Hamilton BE, Ventura SJ, Osterman MJ, Kirmeyer S, et al. Births: final data for 2009. Natl Vital Stat Rep. 2011;60(1):1–70.
McCarthy JJ, Posey BL. Methadone levels in human milk. J Hum Lact. 2000;16(2):115–20.
Metz V, Jagsch R, Ebner N, Wurzl J, Pribasnig A, et al. Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women. Hum Psychopharmacol. 2011;26(6):412–21.
Metz V, Kochl B, Fischer G. Should pregnant women with substance use disorders be managed differently? Neuropsychiatry. 2012;2(1):29–41.
Moore BC, Easton CJ, McMahon TJ. Drug abuse and intimate partner violence: a comparative study of opioid-dependent fathers. Am J Orthopsychiatry. 2011;81(2):218–27.
Najavits LM, Gastfriend DR, Nakayama EY, Barber JP, Blaine J, Frank A, et al. A measure of readiness for substance abuse treatment. Psychometric properties of the RAATE-R interview. Am J Addict. 1997;6(1):74–82.
National Drug Strategy Household Survey Report. 2011. Available from: http://www.fare.org.au/wp-content/uploads/2011/07/Alcohol-Consumption-During-Pregnancy-Final.pdf
National Survey on Drug Use and Health. 2007. Available from: http://www.samhsa.gov/data/2k7/pregCigs/pregCigs.pdf
National Survey on Drug Use and Health 2012. Available from: http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.htm-ch2.6.
National Survey on Drug Use and Health. 2013. Available from: http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.htm#ch2.6
Nature Editorial. Putting gender on the agenda. 2010;465(7299):665.
Newman RG, Gevertz SG. Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy. J Addict Dis. 2011;30(4):318–22.
O’Donnell M, Nassar N, Leonard H, Hagan R, Mathews R, et al. Increasing prevalence of neonatal withdrawal syndrome: population study of maternal factors and child protection involvement. Pediatrics. 2009;123(4):e614–21.
Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155–62.
Osborn DA, Jeffery HE, Cole MJ. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev. 2010 (10):CD002059.
Pajulo M, Savonlahti E, Sourander A, Helenius H, Piha J. Antenatal depression, substance dependency and social support. J Affect Disord. 2001;65(1):9–17.
Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, et al. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012;307(18):1934–40.
Pediatrics AAo. Policy statement: breastfeeding and the use of human milk; 2005.
Pichini S, Puig C, Zuccaro P, Marchei E, Pellegrini M, et al. Assessment of exposure to opiates and cocaine during pregnancy in a Mediterranean city: preliminary results of the “Meconium Project”. Forensic Sci Int. 2005;153(1):59–65.
Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, et al. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50(2):85–94.
Rogers CE, Kidokoro H, Wallendorf M, Inder TE. Identifying mothers of very preterm infants at-risk for postpartum depression and anxiety before discharge. J Perinatol. 2013;33(3):171–6.
Rosen TS, Pippenger CE. Pharmacologic observations on the neonatal withdrawal syndrome. J Pediatr. 1976;88(6):1044–8.
Seligman NS, Salva N, Hayes EJ, Dysart KC, Pequignot EC, et al. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol. 2008;199(4):396.
Stene LE, Dyb G, Jacobsen GW, Schei B. Psychotropic drug use among women exposed to intimate partner violence: A population-based study. Scand J Public Health. 2010;38(5 Suppl):88–95.
Trull TJ, Sher KJ, Minks-Brown C, Durbin J, Burr R. Borderline personality disorder and substance use disorders: a review and integration. Clin Psychol Rev. 2000;20(2):235–53.
Unger A, Jung E, Winklbaur B, Fischer G. Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine. J Addict Dis. 2010;29(2):217–30.
Unger A, Jagsch R, Jones H, Arria A, Leitich H, et al. Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison. Addiction. 2011;106(7):1355–62.
Unger A, Fischer G, Finnegan LP. Drug dependence during pregnancy and the postpartum period. In: Wenzel A, Stuart S, editors. Oxford handbook of perinatal psychology. New York, NY: Oxford University Press; 2013.
United Nations Office on Drug and Crime. World Drug Report 2013 United Nations Publications; 2013.
US National Institutes of Health. NIDA Survey Provides First National Data on Drug Use During Pregnancy. National Pregnancy and Health Survey; 1992.
Velez M, Jansson LM. The opioid dependent mother and newborn dyad: nonpharmacologic care. J Addict Med. 2008;2(3):113–20.
Wachman EM, Hayes MJ, Brown MS, Paul J, Harvey-Wilkes K, et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA. 2013;309(17):1821–7.
Weinberger SM, Kandall SR, Doberczak TM, Thornton JC, Bernstein J. Early weight-change patterns in neonatal abstinence. Am J Dis Child. 1986;140(8):829–32.
Weiner SM, Finnegan LP. Drug withdrawal in the neonate. In: Gardner SL, Carter BS, Enzman-Hines M, Hernandez JA, editors. Merenstein and Gardner’s handbook of neonatal intensive care. 7th ed. St. Louis: Mosby Elsevier; 2011. p. 201–22.
Werler MM, Bower C, Payne J, Serna P. Findings on potential teratogens from a case-control study in Western Australia. Aust N Z J Obstet Gynaecol. 2003;43(6):443–7.
Windsor RA, Boyd NR, Orleans CT. A meta-evaluation of smoking cessation intervention research among pregnant women: improving the science and art. Health Educ Res. 1998;13(3):419–38.
Winklbaur B, Baewert A, Jagsch R, Rohrmeister K, Metz V, et al. Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers. Implications for treatment. Eur Addict Res. 2009;15(3):150–6.
Winklbaur-Hausknost B, Jagsch R, Graf-Rohrmeister K, Unger A, Baewert A, et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Hum Psychopharmacol. 2013;28(1):15–24.
Wojnar-Horton RE, Kristensen JH, Yapp P, Ilett KF, Dusci LJ, et al. Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme. Br J Clin Pharmacol. 1997;44(6):543–7.
Wouldes TA, Woodward LJ. Maternal methadone dose during pregnancy and infant clinical outcome. Neurotoxicol Teratol. 2010;32(3):406–13.
Zahorodny W, Rom C, Whitney W, Giddens S, Samuel M, et al. The neonatal withdrawal inventory: a simplified score of newborn withdrawal. J Dev Behav Pediatr. 1998;19(2):89–93.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Brandt, L., Leifheit, A.K., Finnegan, L.P., Fischer, G. (2014). Management of Substance Abuse in Pregnancy: Maternal and Neonatal Aspects. In: Galbally, M., Snellen, M., Lewis, A. (eds) Psychopharmacology and Pregnancy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54562-7_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-54562-7_12
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-54561-0
Online ISBN: 978-3-642-54562-7
eBook Packages: MedicineMedicine (R0)